So far so good on 510(k) review in US
This article was originally published in RAJ Devices
The general reaction to yesterday's release by the Food and Drug Administration of its keenly awaited road map for the regulatory tightening of the 510(k) premarket notification programme was one of mild relief, tinged with the suspicion that it's not all over yet.
You may also be interested in...
Surveillance and track-and-trace have emerged as the new focus of the UK’s COVID-19 control strategy, but a workable plan is yet to crystalize.
Having rapidly built a large-capacity COVID-19 testing strategy, Germany’s health system leaders are developing the capabilities to avert future outbreaks.
If a post-COVID-19 economic recovery starts properly in September, as some have suggested, how swift would a return to normal be for medtech and life sciences businesses? It depends what the new normal looks like, suggests life sciences legal firm Goodwin. But in the regulatory arena, agencies are working hard to keep market access a priority during the ongoing public health emergency.